Ian Gust
Director/Board Member chez BIOTA HOLDINGS LTD.
Profil
Ian David Gust is currently the Chairman at Bio21 Australia Ltd.
and a Director at Opal Therapeutics, Inc. He is also an Independent Non-Executive Director at Biota Holdings Pty Ltd., a Director at the Australian International Health Institute, a Director at the Pediatric Dengue Vaccine Initiative, and a Professorial Fellow at the University of Melbourne.
In the past, Dr. Gust has worked as the Director of Research & Development at CSL Ltd.
from 1990 to 2000.
He was also a Director at the International AIDS Vaccine Initiative, Inc. from 2010 to 2011.
Additionally, he served as a Non-Executive Director at Opal Therapeutics Pty Ltd., McFarlane Burnet Centre For Medical Research, and Aviragen Therapeutics, Inc. Furthermore, he was a Trustee at the International Vaccine Institute in 2006.
Postes actifs de Ian Gust
| Sociétés | Poste | Début |
|---|---|---|
| BIOTA HOLDINGS LTD. | Director/Board Member | 27/07/2001 |
| Opal Therapeutics, Inc. | Director/Board Member | 09/02/2011 |
| Australian International Health Institute | Director/Board Member | 09/02/2011 |
| Pediatric Dengue Vaccine Initiative | Director/Board Member | 09/02/2011 |
| Bio21 Australia Ltd. | Chairman | 25/01/2012 |
University of Melbourne
 University of Melbourne Other Consumer ServicesConsumer Services The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs. | Corporate Officer/Principal | - |
Anciens postes connus de Ian Gust
| Sociétés | Poste | Fin |
|---|---|---|
International Vaccine Institute
 International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Director/Board Member | 01/01/2006 |
| CSL LIMITED | Chief Tech/Sci/R&D Officer | 01/01/2000 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director/Board Member | - |
| ░░░░░░░░░ ░░░░░░ ░░░░░░ ░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░ ░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CSL LIMITED | Health Technology |
| Entreprise privées | 10 |
|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
| Opal Therapeutics, Inc. | |
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Opal Therapeutics Pty Ltd.
 Opal Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Opal Therapeutics Pty Ltd develops immunotherapy for HIV and Hepatitis C & chronic infection. The company was founded in 2005 and is headquartered in Melbourne, Australia. | Health Technology |
International Vaccine Institute
International Vaccine Institute Miscellaneous Commercial ServicesCommercial Services The International Vaccine Institute develops and distributes vaccines. The non-profit company is based in Seoul, South Korea. Jerome H. Kim has been the CEO of the South Korean company since 2015. | Commercial Services |
| Australian International Health Institute | |
| Pediatric Dengue Vaccine Initiative | |
| Bio21 Australia Ltd. | |
| McFarlane Burnet Centre For Medical Research | |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
